Prostate cancer update.
Recent advances in prostate cancer have focused on treatment strategies in patients with biochemical relapse and novel methods of androgen deprivation therapy such as intermittent therapy, the role of bisphosphonates, and immunotherapeutic approaches. Continued investigation into the mechanism of androgen independence and effective treatments for hormone-refractory disease are described. This article reviews the major advances in prostate cancer published between November 1, 2000, and October 31, 2001.
Rini
Brian I
BI
University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94115, USA. brini@medicine.utsf.edu
Small
Eric J
EJ
D000726:Androgen Antagonists / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008297:Male; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy; D011944:Receptors, Androgen / Q000378:metabolism
D000726:Androgen Antagonists; D004164:Diphosphonates; D011944:Receptors, Androgen; D017430:Prostate-Specific Antigen